Development of novel epigenome therapy for oral cancer based on DNA demathylation
Project/Area Number |
16K20567
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Surgical dentistry
|
Research Institution | Nagoya University |
Principal Investigator |
|
Project Period (FY) |
2016-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | エピジェネティクス / DNA脱メチル化 / TET1 / 口腔癌 / 癌 / ゲノム / 歯学 |
Outline of Final Research Achievements |
Whole exome sequencing announced in 2011 revealed accumulation of genetic and epigenetic alterations in oral cancer. Ten-eleven translocation 1 (TET1) has attracted attention in recent years as epigenome related genes involved in tumorigenesis via DNA demethylation, but TET 1 has not been reported yet in oral cancer and its function is unknown. In this study, detailed genetic and epigenetic analysis using oral cancer cell line and public database was carried out, and it was found that TET1 has function as oncogene in oral cancer. By further developing this research in the future, it is expected that TET 1 can be a novel therapeutic target for oral cancer.
|
Report
(3 results)
Research Products
(10 results)